• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Rates and predictors of hepatitis C virus treatment in HCV–HIV-coinfected subjects

  1. A. A. BUTT1,2,3,
  2. A. C. JUSTICE4,5,
  3. M. SKANDERSON2,
  4. C. GOOD2,3,
  5. C. K. KWOH1,2,3

Article first published online: 25 JUL 2006

DOI: 10.1111/j.1365-2036.2006.03020.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 24, Issue 4, pages 585–591, August 2006

Additional Information

How to Cite

BUTT, A. A., JUSTICE, A. C., SKANDERSON, M., GOOD, C. and KWOH, C. K. (2006), Rates and predictors of hepatitis C virus treatment in HCV–HIV-coinfected subjects. Alimentary Pharmacology & Therapeutics, 24: 585–591. doi: 10.1111/j.1365-2036.2006.03020.x

Author Information

  1. 1

    University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

  2. 2

    VA Pittsburgh Healthcare System, Pittsburgh, PA, USA

  3. 3

    Center for Health Equity Research and Promotion

  4. 4

    Yale University School of Medicine, CT, USA

  5. 5

    VA Connecticut Healthcare System, CT, USA

*Dr A. A. Butt, 3601 Fifth Avenue, Suite 3A, Falk Medical Building, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. E-mail: butta@dom.pitt.edu

Publication History

  1. Issue published online: 25 JUL 2006
  2. Article first published online: 25 JUL 2006
  3. Publication data Submitted 15 March 2006 First decision 27 April 2006 Resubmitted 9 May 2006 Accepted 30 May 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (109K)

References

  • 1
    Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72.
  • 2
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82.
  • 3
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55.
  • 4
    Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451–9.
  • 5
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–50.
  • 6
    Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12: 81–5.
    Direct Link:
  • 7
    Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34: 268–71.
  • 8
    Falck-Ytter YM, Kale HM, Mullen KDM, Sarbah SAM, Sorescu LM, McCullough AJM. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288–92.
  • 9
    Fultz SL, Justice AC, Butt AA, Rabeneck L, Rodriguez-Barradas MC, Weissman S. Testing, referral, and treatment patterns for hepatitis C coinfection in a cohort of veterans with HIV infection. Clin Infect Dis 2003; 36: 1039–46.
  • 10
    Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702–10.
  • 11
    Kramer JR, Giordano TP, Souchek J, El Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42: 309–14.
  • 12
    Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100: 56–63.
    Direct Link:
  • 13
    Giordano TP, Kramer JR, Souchek J, Richardson P, El Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch Intern Med 2004; 164: 2349–54.
  • 14
    Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. The risk of diabetes in HIV infected veterans in the pre- and post-HAART era and the role of hepatitis C virus co-infection. Hepatology 2004; 40: 115–9.
    Direct Link:
  • 15
    Bonino F. Effect of interferon-[alpha] on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 351: 1535–9.
  • 16
    Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15: 689–98.
    Direct Link:
  • 17
    Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196–7.
  • 18
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174–81.
  • 19
    Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999; 341: 1198–205.
  • 20
    Dominitz JA, Maynard C, Billingsley KG, Boyko EJ. Race, treatment, and survival of veterans with cancer of the distal esophagus and gastric cardia. Med Care 2002; 40: 14–26.
  • 21
    Petersen LAM, Normand SL, Leape LLM, McNeil BJM. Comparison of use of medications after acute myocardial infarction in the veterans health administration and medicare. Circulation 2001; 104: 2898–904.
  • 22
    Peterson ED, Shaw LK, DeLong ER, Pryor DB, Califf RM, Mark DB. Racial variation in the use of coronary-revascularization procedures – are the differences real? Do they matter? N Engl J Med 1997; 336: 480–6.
  • 23
    Smola S, Justice AC, Wagner J, Rabeneck L, Weissman S, Rodriguez-Barradas M. Veterans aging cohort three-site study (VACS 3): overview and description. J Clin Epidemiol 2001; 54 (Suppl. 1): S61–76.
  • 24
    Kilbourne AM, Justice AC, Rabeneck L, Rodriguez-Barradas M, Weissman S. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001; 54 (Suppl. 1): S22–8.
View Full Article (HTML) Get PDF (109K)